PE20231169A1 - Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas - Google Patents
Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinasInfo
- Publication number
- PE20231169A1 PE20231169A1 PE2023000716A PE2023000716A PE20231169A1 PE 20231169 A1 PE20231169 A1 PE 20231169A1 PE 2023000716 A PE2023000716 A PE 2023000716A PE 2023000716 A PE2023000716 A PE 2023000716A PE 20231169 A1 PE20231169 A1 PE 20231169A1
- Authority
- PE
- Peru
- Prior art keywords
- administration
- increase
- human subject
- compared
- amount
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 4
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 abstract 1
- 101150092476 ABCA1 gene Proteins 0.000 abstract 1
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 abstract 1
- 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 abstract 1
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 abstract 1
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un metodo para tratar la aterosclerosis y/o una enfermedad cardiovascular aterosclerotica en un individuo humano, comprendiendo el metodo: administrarle una cantidad terapeuticamente eficaz de 2-hidroxipropil-beta-ciclodextrina al individuo humano, donde la cantidad terapeuticamente eficaz es: (a) una cantidad eficaz para aumentar el nivel sistemico y/o en circulacion de uno o mas oxisteroles en el individuo humano en al menos alrededor del 10 % despues de la administracion en comparacion con antes de la administracion; (b) una cantidad eficaz para aumentar la capacidad de disolucion de cristales de colesterol (CCDC) en plasma en al menos alrededor del 10 % luego de la administracion en comparacion con antes de la administracion; (c) una cantidad eficaz para aumentar un nivel de ABCA1 y/o ABCG1 en al menos alrededor del 10 % despues de la administracion en comparacion con antes de la administracion; (d) alrededor de 50 mg/kg a alrededor de 2000 mg/kg; o (e) cualquier combinacion de estos, mediante lo cual se trata la aterosclerosis y/o enfermedad cardiovascular aterosclerotica en el individuo humano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063071257P | 2020-08-27 | 2020-08-27 | |
| PCT/US2021/048084 WO2022047249A1 (en) | 2020-08-27 | 2021-08-27 | Methods for the treatment of cardiovascular disease with cyclodextrins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231169A1 true PE20231169A1 (es) | 2023-07-26 |
Family
ID=80353287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000716A PE20231169A1 (es) | 2020-08-27 | 2021-08-27 | Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240000826A1 (es) |
| EP (1) | EP4203974A1 (es) |
| JP (1) | JP2023543131A (es) |
| KR (1) | KR20230104119A (es) |
| CN (1) | CN116322644A (es) |
| AU (1) | AU2021331487A1 (es) |
| CA (1) | CA3189915A1 (es) |
| CO (1) | CO2023003656A2 (es) |
| CR (1) | CR20230135A (es) |
| IL (1) | IL300805A (es) |
| MX (1) | MX2023002418A (es) |
| PE (1) | PE20231169A1 (es) |
| WO (1) | WO2022047249A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4877778A (en) * | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
| CN104244956B (zh) * | 2012-04-13 | 2020-04-17 | L&F研究有限公司 | 使用环糊精的方法 |
-
2021
- 2021-08-27 EP EP21862882.4A patent/EP4203974A1/en active Pending
- 2021-08-27 KR KR1020237010388A patent/KR20230104119A/ko unknown
- 2021-08-27 AU AU2021331487A patent/AU2021331487A1/en active Pending
- 2021-08-27 WO PCT/US2021/048084 patent/WO2022047249A1/en active Application Filing
- 2021-08-27 MX MX2023002418A patent/MX2023002418A/es unknown
- 2021-08-27 CN CN202180053234.0A patent/CN116322644A/zh active Pending
- 2021-08-27 US US18/023,325 patent/US20240000826A1/en active Pending
- 2021-08-27 PE PE2023000716A patent/PE20231169A1/es unknown
- 2021-08-27 IL IL300805A patent/IL300805A/en unknown
- 2021-08-27 CR CR20230135A patent/CR20230135A/es unknown
- 2021-08-27 JP JP2023513670A patent/JP2023543131A/ja active Pending
- 2021-08-27 CA CA3189915A patent/CA3189915A1/en active Pending
-
2022
- 2022-11-11 US US17/985,762 patent/US20230091966A1/en not_active Abandoned
-
2023
- 2023-03-23 CO CONC2023/0003656A patent/CO2023003656A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230091966A1 (en) | 2023-03-23 |
| IL300805A (en) | 2023-04-01 |
| JP2023543131A (ja) | 2023-10-13 |
| CN116322644A (zh) | 2023-06-23 |
| CA3189915A1 (en) | 2022-03-03 |
| CR20230135A (es) | 2023-07-19 |
| CO2023003656A2 (es) | 2023-08-09 |
| US20240000826A1 (en) | 2024-01-04 |
| MX2023002418A (es) | 2023-07-11 |
| AU2021331487A1 (en) | 2023-03-16 |
| EP4203974A1 (en) | 2023-07-05 |
| WO2022047249A1 (en) | 2022-03-03 |
| KR20230104119A (ko) | 2023-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zheng et al. | Stroke recovery and rehabilitation in 2016: a year in review of basic science and clinical science | |
| Bawaskar et al. | Indian red scorpion envenoming | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| GT200900029A (es) | Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4 | |
| AR072805A1 (es) | Composiciones intranasales formas galenicas y metodos de tratamiento. | |
| CO5590913A2 (es) | Terapia de combinacion antivirica | |
| JP2014139255A5 (es) | ||
| Alisherovna et al. | EFFICACY OF DRUG-FREE THERAPY OF HYPERTENSION DISEASES IN THE EARLY STAGE OF THE DISEASE | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| PE20231169A1 (es) | Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas | |
| AR073514A1 (es) | Metodos de tratamiento de hiperuricemia y estados de enfermedad asociados | |
| Bergman et al. | Escitalopram for antipsychotic nonresponsive visual hallucinosis: eight patients suffering from Charles Bonnet syndrome | |
| Stewart et al. | Fresh frozen plasma in the treatment of ACE inhibitor-induced angioedema | |
| GT200600274A (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado y su uso como agentes farmacétuicos | |
| RU2016136666A (ru) | Составы на основе прогестерона | |
| BR112016029942A2 (pt) | composto, forma de base livre cristalina anidra, composição farmacêutica, método para fabricação de uma forma de base livre cristalina, método de tratamento de uma infecção viral, método de tratar, aliviar, prevenir ou reduzir os sintomas ou exacerbações de asma ou doença pulmonar obstrutiva crônica e método de tratamento de doença mão, pé e boca | |
| Li et al. | Compound Danshen dripping pills for stable angina: meta-analysis of randomized controlled trials | |
| AR061635A1 (es) | Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos | |
| Estabile et al. | The inflammatory nitric oxide mechanism and its participation in cardiac tissue injuries | |
| Sharma et al. | Perioperative myocardial infarction | |
| Virgili | Fusidic acid/betamethasone valerate/tacrolimus | |
| Shader | What is depression and who is in depression studies? | |
| Baha et al. | Massive pulmonary embolism following varicose vein surgery that was successfully treated with thrombolytic therapy | |
| Parkhomenko et al. | Improving efficiency of antioxidant and cytoprotective therapy in patients with NSAID-gastropathy and concomitant ischemic heart disease | |
| Manzurakhon | THE ORIGIN OF GOUT AND METHODS OF ITS TREATMENT |